The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Monday Deal Review: July 6, 2009

B&W_BigNickelLearn more about Neuromed’s deal with CombinatoRx, check out what MedMira’s been doing with all the cash from its equity line, and find out who’s closed deals and who’s just closing doors in this week’s Monday Deal Review

Neuromed-CombinatoRx:

As we noted at the time, Neuromed is merging with CombinatoRx (NASDAQ: CRXX).  The deal has an interesting structure, since it’s occurring almost on the eve of the PDUFA date (this Fall) for Neuromed’s lead product, Exalgo.  Currently, the split of the post-merger CombinatoRx shares is 50/50 between Neuromed and CombinatoRx backers.  However, the longer the delay until FDA approval for Exalgo, the greater the share of the combined company goes to CombinatoRx.  Specifically:

  • FDA approval by the end of 2009 – Neuromed’s backers get 70% of the shares;
  • FDA approval Q1-Q3 2010 –Neuromed’s backers get 60%;
  • FDA approval Q4 2010 — CombinatoRx shareholders keep 60%; and
  • FDA approval after December 2010 (or never): CombinatoRx’s shareholders keep 70%.

Neuromed’s president and CEO Chris Gallen, will be president and CEO of CombinatoRx post-merger.  The In Vivo blog says that “CombinatoRx has been trading at or shed the majority of its value last October after the failure of its lead osteoarthritis candidate, and then restructured in November. Since then it has essentially traded below the value of its cash on hand, making it a prime candidate for a reverse merger.”  Et voilà!

Expansion in China:

Citing China’s US$125 billion investment in April toward healthcare reform, MedMira Inc., (NASDAQ: MMIRF, TSX-V: MIR) entered into a strategic partnership with Triplex International Biosciences Co., Ltd. Triplex has a large customer base and existing diagnostics product line in China.

Wrapping Things Up:

Bookmark and Share
About these ads

5 responses to “Monday Deal Review: July 6, 2009

  1. Pingback: New Data Shows 70% of Canada’s Biotech Companies Have Under 12 Months’ Cash. BIOTECanada’s New Ask: Government Loans. « The Cross-Border Biotech Blog

  2. Pingback: Monday Deal Review: August 17, 2009 « The Cross-Border Biotech Blog

  3. Pingback: MDS Selling Its Analytical Technologies Business for $650 million, Intends to Sell Pharma Services Business Next « The Cross-Border Biotech Blog

  4. Pingback: Monday Biotech Deal Review: September 14, 2009 « The Cross-Border Biotech Blog

  5. Pingback: Monday Biotech Deal Review: March 8, 2010 « The Cross-Border Biotech Blog

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Follow

Get every new post delivered to your Inbox.

Join 126 other followers